Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: The randomized AGITG DYNAMIC-Rectal study.

In the ctDNA-guided arm, 42/150 (28%) with successful testing were ctDNA-positive. Adjuvant chemotherapy was used in 46% vs 77% (P<0.001). 3-year RFS was 76% vs 82% (difference 6%, 95% CI -6% to 17%). The abstract states the sample size precludes conclusions about non-inferiority. Recurrence in untreated ctDNA-negative patients was often lung-only (12/15, 80%).

ASCO Gastrointestinal Cancers Symposium 2024